Immunologic profile of a patient with dyskeratosis congenita

G. L. Clayman, G. Young, E. A. Grimm, D. L. Taylor, S. P. Schantz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The main objective of this study was to determine the biologic response of a patient with dyskeratosis congenita compared to that of six other patients, all with unresectable advanced or recurrent squamous cell carcinoma of the head and neck. Patients received two three-week cycles of continuous infusion recombinant interleukin-2 (TIL-2) (3 x 106 IU/m2/day) and intramuscular interferon-alpha (INF-α) (5 x 106 IU/m2/day). The dyskeratosis congenita patient did not show the lymphocyte proliferative or phenotypic response as seen in the other cancer patients. Phenotypic IL-2 receptor analysis revealed no detectable fluorescence of the p55 or p75 (IL-2 receptors), as expected in the other cancer patients. We conclude that further analysis of other dyskeratosis congenita patients' peripheral blood lymphocytes is critical to further elucidate the role of the IL-2 receptor contributing to their immune deficit.

Original languageEnglish
Pages (from-to)150-157
Number of pages8
JournalImmunology and Allergy Practice
Issue number4
StatePublished - 1992
Externally publishedYes


Dive into the research topics of 'Immunologic profile of a patient with dyskeratosis congenita'. Together they form a unique fingerprint.

Cite this